A5044834906- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
- Chronic Myeloid Leukemia Treatments
- Blood disorders and treatments
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Viral-associated cancers and disorders
- Neuroblastoma Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Neonatal Health and Biochemistry
- CNS Lymphoma Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer Genomics and Diagnostics
- Adolescent and Pediatric Healthcare
- Autoimmune and Inflammatory Disorders Research
Loma Linda University Health Care
2024
Loma Linda University
2023-2024
The University of Texas MD Anderson Cancer Center
2017-2023
Pediatrics and Genetics
2021
University of Southern California
2013-2017
Children's Hospital of Los Angeles
2013-2017
Children's Hospital at Montefiore
2016
Albert Einstein College of Medicine
2016
Montefiore Medical Center
2016
Children's Center
2015
Abstract Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence TA-TMA much higher than prior retrospective studies did not systematically screen. These data have been replicated in multicenter study. Our objective was to determine and risk factors for compare outcomes pediatric HSCT patients with without TA-TMA. Patients were prospectively...
Venetoclax is approved for adult patients with chronic lymphocytic leukemia and acute myeloid leukemia. Expanding its use to the pediatric population currently under investigation, but more robust data are needed. We retrospectively analyzed safety efficacy of venetoclax in children/AYA ALL/LBL. identified 18 (T-cell ALL, n = 7; T-cell LBL, 6; B-cell 5) aged 6-22 years. No new signals were identified; most common toxicity was myelosuppression. deaths occurred within 30 days from start...
The Cornell Assessment for Pediatric Delirium (CAPD) was first proposed by the Acute Lung Injury and Sepsis Investigators Network-Stem Cell Transplantation Cancer Immunotherapy Subgroup MD Anderson CARTOX joint working committees, detection of immune effector cell associated neurotoxicity (ICANS) in pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. It subsequently adopted American Society Cellular Therapy. utility CAPD as a screening tool early diagnosis ICANS has...
Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved decades, and alternative options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells oncolytic viruses (OVs), currently being evaluated both adults children refractory tumors. Because remarkably diverse biologically different from their adult counterparts, more research is required to develop effective regimens for these...
Sinusoidal obstruction syndrome is a potentially fatal complication following hematopoietic cell transplantation, high-intensity chemotherapies and increasingly seen with calicheamicin based leukemia therapies. Paediatric specific European Society for Blood Marrow Transplantation (pEBMT) diagnostic criteria have demonstrated benefit in single center studies compared to historic criteria. Yet, the extent which they been universally implemented remains unclear.
The quest continues for targeted therapies to reduce the morbidity of chemotherapy and improve response resistant leukemia. Adhesion acute lymphoblastic leukemia (ALL) cells bone marrow stromal triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown be effective in CLL down-regulating p-Akt prolonging survival combination with Rituximab; herein we explore...
Research Article13 October 2016Open Access Transparent process Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection mortality Lin Li Department of Pathology, Children's Hospital Los Angeles Saban Institute, Angeles, CA, USA Institute Pharmacology Toxicology, Zhejiang University, Hangzhou, Zhejiang, China Search for more papers by this author Xiaotian Qi Developmental Biology Regenerative Medicine Program,...
Abstract Veno-occlusive disease (VOD) is a rare but potentially life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Although increasing awareness and modern transplant techniques have mitigated risk, the interaction of historic risk factors in current era with posttransplant cyclophosphamide (PTCy) unknown. We performed retrospective single-center analysis adult patients aged ≥18 years undergoing allo-SCT (N = 1561) using predominately PTCy as...
Abstract Primary isolated CNS presentation of HLH is exceedingly rare and typically associated with significant morbidity mortality. We describe an adolescent patient late‐onset, primary a compound heterozygous PRF 1 mutation (c50delT (p.L17 fs); c.1229G>C (p.R410P)), not previously reported this phenotype. He was successfully treated allogeneic HSCT following reduced‐intensity conditioning regimen, despite high pre‐ comorbidity index. Two years after transplant, he alive in disease...
High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR lymphoma treated with HDC/ASCT at our institution between 01/01/2005 12/31/2019. criteria included primary refractory disease/relapse within 1 year, extranodal extension, B symptoms, requiring more than one salvage line, or positron...